BRAF and melanoma: The clinical use of BRAF inhibitors (vemurafenib, dabrafenib, and encorafenib) and MEK inhibitors (trametinib, cobimetinib, and binimetinib) in specific combinations, which have proven to be superior to single-agent therapy, has been shown to be effective in the treatment of melanoma and to significantly improve patients’ progression-free survival and overall survival [9].